Masayuki Nagahashi
8PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Apr 28, 2025
Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan.Yusa Togashi, Masayuki Nagahashi, Aoi Oshiro
|Sep 15, 2024
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer.Ayumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka
|Mar 28, 2024
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer.Masayuki Nagahashi, Yasuo Miyoshi
|Sep 21, 2023
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.Ayako Bun, Masayuki Nagahashi, Mamiko Kuroiwa
|Mar 17, 2023
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.Masayuki Nagahashi, YiWei Ling, Chie Toshikawa
|Jan 09, 2021
Activin a Receptor Type 2A Mutation Affects the Tumor Biology of Microsatellite Instability-High Gastric Cancer.Kizuki Yuza, Masayuki Nagahashi, Hiroshi Ichikawa
Pageof 2
